Skip to main content
SpringerLink
Log in

Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer

  • Short Communication
  • Aclarubicin, Phase Il, Small-Cell Lung Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Aabo K, Mortensen SÅ, Skovsgaard T, Gymoese E (1983) Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity. Cancer Treat Rep 67: 281–282

    Google Scholar 

  2. Abeloff MD, Finkelstein DM, Chang AYC, Camacho FJ, Creech H, Ettinger DS (1985) Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group study. Cancer Treat Rep 69: 451–452

    Google Scholar 

  3. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB, Killmann S-A, Jensen MK, Karle H, Laursen B, Nielsen JB, Nissen NI, Thorling K (1991) Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia 5: 510–516

    Google Scholar 

  4. Jensen PB, Vindeløv L, Roed H, Demant EJF, Sehested M, Skovsgaard T, Hansen HH (1989) In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer 60: 838–844

    Google Scholar 

  5. Jensen PB, Jensen PS, Sehested M, Demant EJF, Sørensen BS, Vindeløv L, Hansen HH (1991) Lack of cross-resistance to aclarubicin in an altered topoisomerase II multidrug resistant (at-MDR) small cell lung cancer (SCLC) cell line. Proc Am Assoc Cancer Res 32:350

    Google Scholar 

  6. Jensen PB, Jensen PS, Demant EJF, Friche E, Sørensen BS, Sehested M, Wassermann K, Vindeløv L, Westergaard O, Hansen HH (1991) Antagonistic effect of aclarubicin on daunorubicin induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 51: 5093–5099

    Google Scholar 

  7. Kramer BS, Birch R, Gockerman JP, Greco A, Prestridge K (1986) Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group trial. Cancer Treat Rep 70: 803–804

    Google Scholar 

  8. Machover D, Gastiaburu J, Delgado M, Goldschmidt E, Hulhoven R, Misset JL, Vassal F de, Tapiero H, Ribaud P, Schwarzenberg L, Mathé G (1984) Phase I-II study of aclarubicin for treatment of acute myeloid leukemia. Cancer Treat Rep 68: 881–886

    Google Scholar 

  9. Oki T, Takeuchi T, Oka S, Umezawa H (1981) New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials. Recent Results Cancer Res 76: 21–40

    Google Scholar 

  10. Pedersen-Bjergaard J, Brincker H, Ellegaard J, Drivsholm A, Freund L, Jensen KB, Jensen MK, Nissen NI (1984) Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunomycin and cytarabine: a phase II trial. Cancer Treat Rep 68: 1233–1238

    Google Scholar 

  11. Skovsgaard T (1987) Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin. Eur J Haematol 38: 7–20

    Google Scholar 

  12. Warrell RP, Arlin ZA, Kempin SJ, Young CW (1982) Phase I–II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia. Cancer Treat Rep 66: 1619–1623

    Google Scholar 

  13. WHO (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, University Hospital Herlev, Herlev, Denmark

    Susanne Kornum Larsen

  2. Department of Oncology 5074, University Hospital Rigshospitalet, 9 Blegdamsvej, DK-2100, Copenhagen, Denmark

    Peter Buhl Jensen & Irene Stilbo

Authors
  1. Peter Buhl Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Kornum Larsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irene Stilbo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jensen, P.B., Larsen, S.K. & Stilbo, I. Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer. Cancer Chemother. Pharmacol. 30, 219–220 (1992). https://doi.org/10.1007/BF00686316

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686316

Keywords

Search

Navigation